Highlighting its commitment towards oncology and women’s health, Myovant Sciences has announced a collaboration with Pfizer to develop and commercialise OrgovyxTM (relugolix) in advanced prostate cancer in the US and Canada. The deal, which is worth up to US$4.4 B, comes a week after Orgovyx gained FDA approval as the first oral androgen deprivation therapy for adults with advanced prostate cancer.